WO2022064079A1 - Terapia metabólica del cáncer - Google Patents
Terapia metabólica del cáncer Download PDFInfo
- Publication number
- WO2022064079A1 WO2022064079A1 PCT/ES2020/070571 ES2020070571W WO2022064079A1 WO 2022064079 A1 WO2022064079 A1 WO 2022064079A1 ES 2020070571 W ES2020070571 W ES 2020070571W WO 2022064079 A1 WO2022064079 A1 WO 2022064079A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- oil
- composition
- use according
- diet
- Prior art date
Links
- 230000002503 metabolic effect Effects 0.000 title abstract description 13
- 238000011275 oncology therapy Methods 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 168
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 166
- 201000011510 cancer Diseases 0.000 claims abstract description 138
- 150000001413 amino acids Chemical class 0.000 claims abstract description 87
- 235000021405 artificial diet Nutrition 0.000 claims abstract description 61
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 32
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 30
- 150000002632 lipids Chemical class 0.000 claims abstract description 30
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 24
- 229930182817 methionine Natural products 0.000 claims abstract description 24
- 229940024606 amino acid Drugs 0.000 claims description 75
- 235000001014 amino acid Nutrition 0.000 claims description 75
- 238000011282 treatment Methods 0.000 claims description 74
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 239000004615 ingredient Substances 0.000 claims description 28
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 23
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 23
- 229960004117 capecitabine Drugs 0.000 claims description 23
- 235000018102 proteins Nutrition 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 21
- 206010038389 Renal cancer Diseases 0.000 claims description 21
- 201000010982 kidney cancer Diseases 0.000 claims description 21
- 239000002246 antineoplastic agent Substances 0.000 claims description 20
- 229940041181 antineoplastic drug Drugs 0.000 claims description 20
- 206010009944 Colon cancer Diseases 0.000 claims description 19
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 19
- 229960001796 sunitinib Drugs 0.000 claims description 19
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 18
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 18
- 235000018417 cysteine Nutrition 0.000 claims description 18
- 239000004471 Glycine Substances 0.000 claims description 17
- 150000001720 carbohydrates Chemical class 0.000 claims description 17
- 239000004475 Arginine Substances 0.000 claims description 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 16
- 235000009697 arginine Nutrition 0.000 claims description 16
- 235000014633 carbohydrates Nutrition 0.000 claims description 16
- 239000005018 casein Substances 0.000 claims description 16
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 16
- 235000021240 caseins Nutrition 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 16
- 208000029742 colonic neoplasm Diseases 0.000 claims description 15
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 13
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 13
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 13
- 229960004316 cisplatin Drugs 0.000 claims description 13
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 13
- 229960003067 cystine Drugs 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 201000001441 melanoma Diseases 0.000 claims description 12
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 12
- 229930003231 vitamin Natural products 0.000 claims description 12
- 235000013343 vitamin Nutrition 0.000 claims description 12
- 239000011782 vitamin Substances 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 10
- 239000011707 mineral Substances 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 239000003797 essential amino acid Substances 0.000 claims description 9
- 238000001050 pharmacotherapy Methods 0.000 claims description 9
- 150000003839 salts Chemical group 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 239000003240 coconut oil Substances 0.000 claims description 8
- 235000019864 coconut oil Nutrition 0.000 claims description 8
- 235000020776 essential amino acid Nutrition 0.000 claims description 8
- 150000002148 esters Chemical group 0.000 claims description 8
- 239000003925 fat Substances 0.000 claims description 8
- 235000019197 fats Nutrition 0.000 claims description 8
- 239000004006 olive oil Substances 0.000 claims description 8
- 235000008390 olive oil Nutrition 0.000 claims description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 229960001231 choline Drugs 0.000 claims description 7
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 7
- 229960002949 fluorouracil Drugs 0.000 claims description 7
- 235000016709 nutrition Nutrition 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 235000009582 asparagine Nutrition 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 235000014304 histidine Nutrition 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 235000008521 threonine Nutrition 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 5
- 206010057644 Testis cancer Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 229960003301 nivolumab Drugs 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- 229940119224 salmon oil Drugs 0.000 claims description 5
- 201000008261 skin carcinoma Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- 201000003120 testicular cancer Diseases 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- 240000007594 Oryza sativa Species 0.000 claims description 4
- 235000007164 Oryza sativa Nutrition 0.000 claims description 4
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 235000012343 cottonseed oil Nutrition 0.000 claims description 4
- 239000002385 cottonseed oil Substances 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 239000000944 linseed oil Substances 0.000 claims description 4
- 235000021388 linseed oil Nutrition 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 235000009566 rice Nutrition 0.000 claims description 4
- 235000005713 safflower oil Nutrition 0.000 claims description 4
- 239000003813 safflower oil Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 3
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 3
- 108010069236 Goserelin Proteins 0.000 claims description 3
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 3
- 102000000588 Interleukin-2 Human genes 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 3
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 3
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- 229960000853 abiraterone Drugs 0.000 claims description 3
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229960002932 anastrozole Drugs 0.000 claims description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 3
- 239000010775 animal oil Substances 0.000 claims description 3
- 230000002280 anti-androgenic effect Effects 0.000 claims description 3
- 229940046836 anti-estrogen Drugs 0.000 claims description 3
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 3
- 230000000340 anti-metabolite Effects 0.000 claims description 3
- 239000000051 antiandrogen Substances 0.000 claims description 3
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 3
- 229940100197 antimetabolite Drugs 0.000 claims description 3
- 239000002256 antimetabolite Substances 0.000 claims description 3
- 239000003886 aromatase inhibitor Substances 0.000 claims description 3
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 3
- 229950002916 avelumab Drugs 0.000 claims description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 3
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 3
- 229960001573 cabazitaxel Drugs 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 201000007455 central nervous system cancer Diseases 0.000 claims description 3
- 229960005395 cetuximab Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940044683 chemotherapy drug Drugs 0.000 claims description 3
- 235000005687 corn oil Nutrition 0.000 claims description 3
- 239000002285 corn oil Substances 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 238000011393 cytotoxic chemotherapy Methods 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 239000008157 edible vegetable oil Substances 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 229960001433 erlotinib Drugs 0.000 claims description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 3
- 239000000328 estrogen antagonist Substances 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- 229960002074 flutamide Drugs 0.000 claims description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002913 goserelin Drugs 0.000 claims description 3
- 238000001794 hormone therapy Methods 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 229960005386 ipilimumab Drugs 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- 235000014666 liquid concentrate Nutrition 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 230000000394 mitotic effect Effects 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 3
- 229960000572 olaparib Drugs 0.000 claims description 3
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229960001756 oxaliplatin Drugs 0.000 claims description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 229960004618 prednisone Drugs 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 229960003787 sorafenib Drugs 0.000 claims description 3
- 235000014347 soups Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- 238000002626 targeted therapy Methods 0.000 claims description 3
- 229960004964 temozolomide Drugs 0.000 claims description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 3
- 229960001278 teniposide Drugs 0.000 claims description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 229960000575 trastuzumab Drugs 0.000 claims description 3
- 229960003862 vemurafenib Drugs 0.000 claims description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- 229960004355 vindesine Drugs 0.000 claims description 3
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 3
- 229960002066 vinorelbine Drugs 0.000 claims description 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 3
- 241000252203 Clupea harengus Species 0.000 claims description 2
- 235000019482 Palm oil Nutrition 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 244000294611 Punica granatum Species 0.000 claims description 2
- 235000014360 Punica granatum Nutrition 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 244000098338 Triticum aestivum Species 0.000 claims description 2
- 235000014121 butter Nutrition 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims description 2
- 239000010460 hemp oil Substances 0.000 claims description 2
- 235000019514 herring Nutrition 0.000 claims description 2
- 235000013310 margarine Nutrition 0.000 claims description 2
- 239000003264 margarine Substances 0.000 claims description 2
- 239000002540 palm oil Substances 0.000 claims description 2
- 235000015927 pasta Nutrition 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- 239000010491 poppyseed oil Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000008171 pumpkin seed oil Substances 0.000 claims description 2
- 239000003760 tallow Substances 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000010698 whale oil Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims 1
- 235000005911 diet Nutrition 0.000 abstract description 120
- 230000037213 diet Effects 0.000 abstract description 115
- 241000699670 Mus sp. Species 0.000 abstract description 83
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 12
- 238000001727 in vivo Methods 0.000 abstract description 5
- 230000008859 change Effects 0.000 abstract description 3
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 208000037819 metastatic cancer Diseases 0.000 abstract description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 abstract description 2
- 238000011458 pharmacological treatment Methods 0.000 abstract description 2
- 238000010171 animal model Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 135
- 230000004083 survival effect Effects 0.000 description 32
- 229940079593 drug Drugs 0.000 description 24
- 239000003814 drug Substances 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 235000021590 normal diet Nutrition 0.000 description 12
- 206010006895 Cachexia Diseases 0.000 description 11
- 230000004075 alteration Effects 0.000 description 11
- 235000007882 dietary composition Nutrition 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 9
- 206010061818 Disease progression Diseases 0.000 description 9
- 230000005750 disease progression Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 208000022531 anorexia Diseases 0.000 description 7
- 206010061428 decreased appetite Diseases 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- -1 salmon oil Substances 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 6
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 6
- 235000005282 vitamin D3 Nutrition 0.000 description 6
- 239000011647 vitamin D3 Substances 0.000 description 6
- 235000019143 vitamin K2 Nutrition 0.000 description 6
- 239000011728 vitamin K2 Substances 0.000 description 6
- 229940021056 vitamin d3 Drugs 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 3
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 3
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 3
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 239000011665 D-biotin Substances 0.000 description 3
- 235000000638 D-biotin Nutrition 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 3
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 3
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- FIXLYHHVMHXSCP-UHFFFAOYSA-H azane;dihydroxy(dioxo)molybdenum;trioxomolybdenum;tetrahydrate Chemical compound N.N.N.N.N.N.O.O.O.O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O[Mo](O)(=O)=O.O[Mo](O)(=O)=O.O[Mo](O)(=O)=O FIXLYHHVMHXSCP-UHFFFAOYSA-H 0.000 description 3
- UNTBPXHCXVWYOI-UHFFFAOYSA-O azanium;oxido(dioxo)vanadium Chemical compound [NH4+].[O-][V](=O)=O UNTBPXHCXVWYOI-UHFFFAOYSA-O 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 3
- 229940116318 copper carbonate Drugs 0.000 description 3
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960002413 ferric citrate Drugs 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000000395 magnesium oxide Substances 0.000 description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
- 235000012245 magnesium oxide Nutrition 0.000 description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 3
- 239000011656 manganese carbonate Substances 0.000 description 3
- 235000006748 manganese carbonate Nutrition 0.000 description 3
- 229940093474 manganese carbonate Drugs 0.000 description 3
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 description 3
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 3
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 3
- 230000004066 metabolic change Effects 0.000 description 3
- ATYNVYNPWGEMMI-UHFFFAOYSA-H nickel(2+);carbonate;tetrahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[Ni+2].[Ni+2].[Ni+2].[O-]C([O-])=O ATYNVYNPWGEMMI-UHFFFAOYSA-H 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000001508 potassium citrate Substances 0.000 description 3
- 229960002635 potassium citrate Drugs 0.000 description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 3
- 235000011082 potassium citrates Nutrition 0.000 description 3
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 3
- 239000001230 potassium iodate Substances 0.000 description 3
- 235000006666 potassium iodate Nutrition 0.000 description 3
- 229940093930 potassium iodate Drugs 0.000 description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 description 3
- 235000011151 potassium sulphates Nutrition 0.000 description 3
- ZFVHBEKVAITXHW-UHFFFAOYSA-J potassium;chromium(3+);disulfate;dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[K+].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZFVHBEKVAITXHW-UHFFFAOYSA-J 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 3
- 201000004193 respiratory failure Diseases 0.000 description 3
- 229940108325 retinyl palmitate Drugs 0.000 description 3
- 235000019172 retinyl palmitate Nutrition 0.000 description 3
- 239000011769 retinyl palmitate Substances 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 239000011655 sodium selenate Substances 0.000 description 3
- 235000018716 sodium selenate Nutrition 0.000 description 3
- 229960001881 sodium selenate Drugs 0.000 description 3
- PHIQPXBZDGYJOG-UHFFFAOYSA-N sodium silicate nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-][Si]([O-])=O PHIQPXBZDGYJOG-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 3
- 239000011747 thiamine hydrochloride Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 229940041603 vitamin k 3 Drugs 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 239000011667 zinc carbonate Substances 0.000 description 3
- 235000004416 zinc carbonate Nutrition 0.000 description 3
- 229910000010 zinc carbonate Inorganic materials 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 206010055114 Colon cancer metastatic Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 230000009946 DNA mutation Effects 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 238000011903 nutritional therapy Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 235000000891 standard diet Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 206010049238 Food aversion Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 108010055615 Zein Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 125000001314 canonical amino-acid group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- GGWBHVILAJZWKJ-UHFFFAOYSA-N dimethyl-[[5-[2-[[1-(methylamino)-2-nitroethenyl]amino]ethylsulfanylmethyl]furan-2-yl]methyl]azanium;chloride Chemical compound Cl.[O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-UHFFFAOYSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 208000029382 endometrium adenocarcinoma Diseases 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 208000026535 luminal A breast carcinoma Diseases 0.000 description 1
- 208000026534 luminal B breast carcinoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940093914 potassium sulfate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960002812 sunitinib malate Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000009825 uterine corpus cancer Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940043825 zinc carbonate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/24—Cellulose or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0604—Alanine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0606—Arginine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/061—Aspartic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/062—Glutamine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0624—Histidine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0626—Isoleucine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0628—Leucine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/063—Lysine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0632—Methionine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0638—Phenylalanine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0648—Threonine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/065—Tryptophan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0654—Valine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
- A23V2250/304—Choline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5108—Cellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5118—Starch
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/628—Saccharose, sucrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to an artificial diet composition for use in the treatment of cancer characterized in that it comprises specific amino acids in controlled amounts, present in the composition in free, salt, ester form and/or provided by a source. of amino acids such as a protein, said artificial diet composition further comprising carbohydrates and lipids plus other ingredients, such as vitamins, minerals, choline and optionally a water-based and/or pharmaceutical excipient.
- composition of the present invention has been shown to be effective for the treatment of cancer in subjects, such as mammals, as confirmed by experimental work showing the high survival rate of mice treated with said artificial diet compositions.
- Pharmacotherapy is the usual treatment for patients with metastases. When the disease spreads and surgery and radiotherapy are no longer curative, pharmacotherapy becomes the main form of treatment. Pharmacotherapy can prolong the lives of patients and palliate some symptoms related to the disease. However, it does not normally cure the disease. The low efficacy of existing antineoplastic drugs is reflected in the low survival rates of patients diagnosed with the most common metastatic cancers.
- Cancer drug therapy can also fail because most drugs preferentially target dividing cells. Resting and slowly proliferating cancer cells, such as CSCs, normally resist therapy. In addition, some resting and slowly proliferating cancer cells are located in poorly vascularized tumor areas. Since antineoplastic drugs reach cells through the blood, tumor cells located in these areas will be exposed to lower concentrations of drug than normal cells (which have an adequate blood supply). This factor reduces the already limited selectivity of existing antineoplastic drugs and contributes to therapy failure.
- the basis for the development of selective antineoplastic therapies is similar to that for the development of selective anti-infective therapies.
- the goal is to kill the infectious agent or cancer cells without doing much harm to the patient.
- the way is to find important and exploitable differences between our cells and the infectious agent, or between our normal cells and cancer cells.
- cancer cells have extremely altered DNA. As explained elsewhere [121], if you look at most tumor cells, it looks like someone has detonated a bomb in the nucleus. There are large pieces of attached chromosomes and gains and losses of entire chromosomes in most tumor cells [12,13]. The karyotype of some tumor cells is strikingly different from that of normal cells; for example, some studies have reported malignant cells with more than 100 chromosomes (http://cgap.nci.nih.gov/Chromosomes/Mitelman). Within chromosomes, thousands of DNA mutations and epigenetic alterations are present in many tumors [14-16].
- a demanding cellular environment can be created without drugs. Because surgery and radiotherapy cannot eliminate unlocalized tumor cells, it is often assumed that pharmacotherapy is the only possible way to successfully treat patients with metastases. Upon entering the bloodstream, a drug can reach and possibly destroy any unlocalized cancer cells. Although cancer cells can be killed by giving a cytotoxic agent, they can also be killed by restricting something they need to survive. The result appears to be the same; however, treating cancer cells without drugs can overcome many cancer cell drug resistance mechanisms (eg, there are no drugs to pump out of cells via ABC transporters). In addition, the location of cancer cells in poorly vascularized tumor areas may not compromise the efficacy of restraint therapy.
- Patent document WO 2017/144877 describes a dietary product for use in the treatment of cancer comprising a plurality of amino acids, comprising all essential amino acids and lacking at least two non-essential amino acids selected from the group consisting of: glycine , serine, cysteine, tyrosine and arginine.
- Suitable combinations of non-essential amino acids not present in dietary compositions are: glycine, serine, and cysteine; glycine, serine and arginine; glycine, serine and tyrosine; glycine, serine, arginine, and cysteine; glycine, serine, tyrosine, and cysteine; cistern and arginine; cistern and tyrosine; cistern and glycine; cisterna, tyrosine and arginine; or glycine, serine, arginine, tyrosine, and cysteine.
- the dietary product may further comprise methionine at a level of less than 25 mg/kg subject body weight/day or less than 20 mg/kg/day or less than 18 mg/kg/day or less than 16 mg/kg /day.
- Patent document WO2017/053328 describes cancer treatment methods by identifying nutritional weaknesses of cancer cells and using nutritional therapy to suppress cancer by putting a subject on a diet that deprives cancer cells of a nutrient necessary for cell proliferation and growth. Cancer. The invention also discloses that said nutritional therapy can be used to enhance the efficacy of current cancer treatments.
- the amino acid-containing supplement contains neither cysteine nor cystine, thus reducing the patient's daily intake of said amino acids from 70-100%.
- Patent document US2013/0330419 refers to a dietary composition for a patient with a tumor, which includes depleted or reduced concentrations of amino acids of at least 50% reduction of the normal consumption of at least one amino acid selected from the group consisting of: arginine, glutamine, methionine, asparagine, phenylalanine, histidine, glycine, tryptophan, leucine, threonine, valine, cystine, isoleucine, lysine, aspartic acid, and tyrosine.
- the invention contemplates a dietary composition useful for the treatment of breast cancer, wherein the dietary composition includes depleted or reduced amino acid concentrations of at least one of: Arg, Gln, Asn, Phe and His.
- the concentration of amino acids is depleted or reduced with respect to Gln, Gly, Trp, Arg, Leu, His and Met.
- the concentration of amino acids is depleted or reduced with respect to His, Gln, Asn, Cys, Leu, Met and Trp.
- the concentration of amino acids is depleted or reduced with respect to Thr, Gly, Met, Cys, Phe, Tyr, Trp, Asn and Val.
- the concentration of amino acids is depleted or reduced with respect to Met, Cys, Tyr, Leu and Asp.
- Patent document EP1572093 discloses methods of preventing various conditions, in particular cancer and conditions associated with cancer treatment, including metastasis by administering glutamine or a pharmaceutically acceptable salt thereof.
- this patent discloses the coadministration of glutamine and an effective amount of a carbohydrate, such as a saccharide.
- the present invention is therefore faced with the problem of providing an effective antineoplastic artificial diet composition, as well as methods of using the same.
- dry composition encompasses all ingredients in the artificial diet composition of the present invention, except water, eg, mixtures of amino acids, proteins, carbohydrates, carbon, lipids, choline, vitamins and minerals.
- subject or “patient” are used interchangeably herein and refer to a vertebrate, preferably a mammal. Mammals include, but are not limited to, humans.
- the terms “treat”, “treatment” and the like are used herein, without limitation, to mean obtaining a desired pharmacological and/or physiological effect.
- the effect may be prophylactic in terms of completely or partially preventing a disorder or signs or symptoms thereof, and/or it may be therapeutic in terms of amelioration of symptoms of disease or infection, or partial or complete cure for a disorder and /or adverse effect attributed to the disorder.
- the given viscosity characteristics are provided by measurement by methods known to one of ordinary skill in the art, including the use of various types of viscometers and rheometers.
- An object of the present invention is an artificial diet composition for use in the treatment and/or prevention of cancer comprising (based on the total weight of the dry ingredient composition):
- leucine is present in the composition as part of the amino acid mixture in an amount of ⁇ 10% by weight with respect to the total weight of the composition of dry ingredients and methionine is present in the composition as part of the amino acid mixture in an amount of ⁇ 0.6% by weight with respect to the total weight of the composition of dry ingredients.
- An additional object of the present invention is an artificial diet composition for use according to the preceding paragraph, characterized in that leucine is present in an amount of between 0.5 to 6% by weight and methionine is present in an amount of between 0.1 to 0.6% by weight based on the total weight of the dry ingredient composition.
- An additional object of the present invention is an artificial diet composition for use according to any preceding paragraph, characterized in that the mixture of amino acids is a mixture of essential and non-essential amino acids, selected from the group consisting of: leucine, isoleucine, valine, methionine, lysine, phenylalanine, tryptophan, threonine, histidine, asparagine, alanine, arginine, acid aspartic acid, cysteine/cystine, glutamic acid, glutamine, proline, glycine, tyrosine, serine, and mixtures thereof.
- the mixture of amino acids is a mixture of essential and non-essential amino acids, selected from the group consisting of: leucine, isoleucine, valine, methionine, lysine, phenylalanine, tryptophan, threonine, histidine, asparagine, alanine, arginine, acid aspartic acid, cyste
- An additional object of the present invention is an artificial diet composition for use according to any preceding paragraph, characterized in that the amino acids are in the free form, salt form, ester form and/or in the form of a peptide, polypeptide or protein. .
- An additional object of the present invention is an artificial diet composition for use according to any preceding paragraph, characterized in that the amino acids present in the composition are a combination of amino acids in free form and as a protein.
- An additional object of the present invention is an artificial diet composition for use according to the previous paragraph, characterized in that the protein is casein.
- An additional object of the present invention is an artificial diet composition for use according to any preceding paragraph, characterized in that the lipid ingredient is present in an amount of from 0-14% by weight with respect to the total weight of the dry composition.
- An additional object of the present invention is an artificial diet composition for use according to the previous paragraph, characterized in that the lipid ingredient is selected from any edible vegetable or animal oil, selected from: rapeseed oil, sunflower oil, corn, soybean oil, linseed oil, rice oil, safflower oil, olive oil, coconut oil, cottonseed oil, fish oil, and mixtures thereof.
- the lipid ingredient is selected from any edible vegetable or animal oil, selected from: rapeseed oil, sunflower oil, corn, soybean oil, linseed oil, rice oil, safflower oil, olive oil, coconut oil, cottonseed oil, fish oil, and mixtures thereof.
- An additional object of the present invention is an artificial diet composition for use according to the previous paragraphs, characterized in that the one or more lipid ingredients is selected from the group consisting of: olive oil, coconut oil, salmon oil, corn oil, soybean oil, canola oil, rapeseed oil, sunflower oil, linseed oil, rice oil, safflower oil, cottonseed oil, palm oil, castor oil, castor oil peanut oil, wheat oil, pumpkin seed oil, poppy seed oil, hemp oil, pomegranate seed oil, cod oil, herring oil, whale oil, seal oil, margarine, butter, fat, tallow and mixtures thereof.
- the one or more lipid ingredients is selected from the group consisting of: olive oil, coconut oil, salmon oil, corn oil, soybean oil, canola oil, rapeseed oil, sunflower oil, linseed oil, rice oil, safflower oil, cottonseed oil, palm oil, castor oil, castor oil peanut oil, wheat oil, pumpkin seed oil, poppy seed oil, hemp
- An additional object of the present invention is an artificial diet composition for use according to any preceding paragraph, characterized in that the carbohydrates can be selected from the group consisting of: sucrose, cellulose, starch and mixtures thereof.
- An additional object of the present invention is a diet composition artificial for use according to any preceding paragraph, characterized in that it is in a form suitable for oral administration.
- An additional object of the present invention is an artificial diet composition for use according to the previous paragraph, characterized in that it is in a solid, semi-solid or liquid form and is selected from: dry powder, shake, liquid concentrates, ready-to-drink beverage, cold or shelf-stable beverage, soup, pasta, puree, nutrition bar.
- An additional object of the present invention is an artificial diet composition for use according to any preceding paragraph, characterized in that the treatment of cancer comprises: kidney cancer, lung cancer, colon cancer, breast cancer, melanoma, ovarian cancer, prostate cancer, pancreatic cancer, liver cancer, endometrial cancer, cervical cancer, bladder cancer, esophageal cancer, gastric cancer, head and neck cancers, leukemia, lymphomas, non-melanoma skin cancers, sarcomas, cancers of the central nervous system, testicular cancer, thyroid cancer, and cancer of unknown primary site.
- the treatment of cancer comprises: kidney cancer, lung cancer, colon cancer, breast cancer, melanoma, ovarian cancer, prostate cancer, pancreatic cancer, liver cancer, endometrial cancer, cervical cancer, bladder cancer, esophageal cancer, gastric cancer, head and neck cancers, leukemia, lymphomas, non-melanoma skin cancers, sarcomas, cancers of the central nervous system, testicular cancer, thyroid
- An additional object of the present invention is an artificial diet composition for use according to any preceding paragraph, characterized in that the treatment comprises treatment cycles of two to twelve weeks with four to six daily doses.
- An additional object of the present invention is an artificial diet composition for use according to any preceding paragraph, characterized in that it further comprises water or a water-based vehicle.
- An additional object of the present invention is a pharmaceutical composition comprising the artificial diet composition of any previous paragraph together with a pharmaceutically acceptable excipient or vehicle, for use in the treatment of cancer.
- An additional object of the present invention is a pharmaceutical composition as defined in the previous paragraph for use in the treatment of cancer comprising: kidney cancer, lung cancer, colon cancer, breast cancer, melanoma, ovarian cancer, prostate cancer, pancreatic cancer, liver cancer, endometrial cancer, cervical cancer, bladder cancer, esophageal cancer, gastric cancer, head and neck cancers, leukemia, lymphomas, non-melanoma skin cancers, sarcomas, cancers of the central nervous system, testicular cancer, thyroid cancer, and cancer of unknown primary site.
- An additional object of the present invention is a pharmaceutical composition as defined in the previous paragraphs, characterized in that the treatment comprises the joint administration of the pharmaceutical composition together with any type of pharmacotherapy, including cytotoxic chemotherapy drugs such as alkylating agents (eg, cisplatin, carboplatin, oxaliplatin, cyclophosphamide, temozolomide, hydroxyurea, etc.), antimetabolites (eg, fluorouracil, capecitabine, gemcitabine, methotrexate, cytarabine, etc), mitotic inhibitors (eg, paclitaxel, docetaxel, cabazitaxel, vincristine, vinblastine, vinorelbine, vindesine, etc), topoisomerase inhibitors (eg, etoposide, teniposide, irinotecan, topotecan, doxorubicin, epirubicin, etc.
- cytotoxic chemotherapy drugs such as alkylating agents (eg,
- hormonal therapy for example, antiestrogens such as tamoxifen, aromatase inhibitors such as anastrozole, LHRH agonists such as goserelin, antiandrogens such as abiraterone and flutamide, corticosteroids such as dexamethasone and prednisone, etc.
- immunotherapies for example, anti-PD1 such as nivolumab, anti-PDL1 such as avelumab, anti-CTLA4 such as ipilimumab, cytokines such as interleukin -2 and interferon, etc.
- targeted therapies for example, anti-VEGF agents such as bevacizumab, anti-VEGFR such as sunitinib and sorafenib, anti-EGFR such as cetuximab or erlotinib, anti-HER2 such as trastuzumab, anti- PARP such as olaparib, anti-BRAF such as ve
- An additional object of the present invention is a pharmaceutical composition as defined in the previous paragraph, characterized in that said joint administration comprises the sequential, concomitant or simultaneous administration of the active ingredients.
- An additional object of the present invention is a pharmaceutical composition as defined in the previous paragraphs, characterized in that the treatment comprises administering to a subject in need thereof an effective amount of the pharmaceutical composition during surgery and/or radiotherapy treatment.
- FIG. 1 Antineoplastic activity of diet P2, sunitinib, and anti-PD1 in mice with kidney cancer (intraperitoneal model)
- FIG. 1 Antineoplastic activity of diet P10 and capecitabine in mice with colon cancer (intraperitoneal model)
- FIG. 3 Antineoplastic activity of diet P6 and capecitabine in mice with colon cancer (intravenous model)
- Figure 5 Cell viability after treatment with MO, M1, M2, M3, 5-FU, cisplatin, doxorubicin and paclitaxel diets DETAILED DESCRIPTION OF THE INVENTION All cancer cells acquire DNA alterations and thrive in a relatively constant metabolic environment. In this normal environment, cancer cells can grow uncontrollably, can escape the immune system, and can generally resist most types of systemic therapies.
- the aim of the present invention is to change the normal metabolic environment of cancer cells using artificial diets in which the levels and ratios of specific amino acids and lipids are manipulated. Normal cells will use their normal DNA to adapt to the new environment and resist the therapy. Due to their DNA alterations, cancer cells may not be able to fully adapt to the new metabolic environment and may therefore die.
- Amino acid restriction can cause cancer cell death. Briefly, cell survival requires protein synthesis. Proteins are continually degraded and replaced by new ones to ensure a constant supply of functional proteins [23,24]. Protein synthesis in humans requires sufficient levels of all 20 canonical amino acids (AAs). An insufficient supply of just one of them for a long enough time will compromise protein synthesis and result in cell death. Many proteinogenic AAs are also needed for other cellular processes. All cancer cells, including CSCs, non-dividing cancer cells, or any type of resistant cancer cell, will die if they do not get sufficient levels of any proteinogenic AA.
- AAs canonical amino acids
- AA restriction can result in the selective destruction of cancer cells.
- Human cells cannot synthesize nine of the 20 proteinogenic AAs; these nine AAs are called essential AAs (EAAs) and need to be taken from the diet. The rest, the so-called non-essential AAs (NEAAs), can be synthesized from glucose and some essential and non-essential AAs.
- NEAAs non-essential AAs
- NSAA biosynthesis requires a variety of enzymes that catalyze various reactions and pathways. Some genes that code for these enzymes may not be functional in cancer cells; they may be mutated, silenced, or located on missing chromosomes. However, since dietary proteins provide each of the 20 AAs required for protein synthesis, these DNA alterations would not jeopardize cancer cell survival.
- Arginine deprivation probably forced the cells to activate a variety of genetic adaptation programs, which were functional in normal cells but not in cancer cells. Accumulation of DNA alterations in cancer cells during carcinogenesis likely inactivated the genetic programs required to adapt and survive in the new environment created when arginine was deprived.
- the present inventors have surprisingly discovered that in order for an amino acid manipulated diet to be satisfactory, in terms of increased survival rate of the patient taking said diet when compared to a patient not taking said dietary composition , it is essential to control the consumption of specific amino acids and also to control the amounts of these specific amino acids that are going to be taken, so that the daily consumption of a specific combination of amino acids changes to the specific amounts.
- the authors of the present invention have found that the antitumor activity of a diet manipulated into amino acids depends on the interaction of controlled amounts of a group of specific amino acids.
- the activity of the engineered diet in amino acids may also depend on the levels of other dietary constituents such as lipids.
- Lipids participate in multiple cellular processes crucial for tumor development and disease progression. For example, they are essential for the synthesis of cell membranes of new cancer cells, they provide substrates for energy production, they are the starting point for the biosynthesis of cellular mediators highly involved in cancer such as prostaglandin E2 (PGE2).
- PGE2 promotes angiogenesis, activates cancer stem cell division, blocks the type 1 interferon-dependent innate immune response, induces macrophage reprogramming to the M2 subtype, and promotes cancer cachexia [26,27]-
- Cachexia derives from the Greek word meaning "bad condition” and is characterized by anorexia (loss of appetite), weight loss, progressive muscle wasting, and chronic nausea. Other observed effects are changes in body composition, alterations in carbohydrate, protein, and lipid metabolism, and depression. Cancer-related metabolic changes lead to a preferential reduction in body mass as a source of calories. In this way, cachexia differs from simple starvation, where the body will metabolize fat stores and protect body mass.
- Anorexia loss of appetite and food consumption are observed in 50% of newly diagnosed cancer patients. Early satiety, taste and smell disturbances, food aversions, nausea, and vomiting are all contributing factors to anorexia.
- Anorexia-cachexia syndrome is a major cause of morbidity and mortality in cancer patients.
- the anorexia/cachexia syndrome characterized by progressive nutritional changes, weakness, and wasting, is frequently debilitating and life-threatening over a long period of time. Therefore, a successful amino acid-manipulated diet for cancer treatment should not only interfere with cancer cell proliferation, but also create a metabolic environment to prevent or ameliorate the syndrome. anorexia/cachexia.
- the present invention refers, therefore, to an artificial diet composition for use in the treatment of cancer characterized in that it comprises specific amino acids in controlled amounts, present in the composition in free form, salt, ester and/or they are provided by an amino acid source, such as protein, together with carbohydrates and lipids plus additional ingredients such as vitamin and mineral mixtures, and optionally a dietary excipient and/or pharmaceutical carrier.
- an amino acid source such as protein
- carbohydrates and lipids plus additional ingredients such as vitamin and mineral mixtures
- additional ingredients such as vitamin and mineral mixtures
- optionally a dietary excipient and/or pharmaceutical carrier optionally a dietary excipient and/or pharmaceutical carrier.
- a first embodiment of the present invention is an artificial diet composition comprising from about 4 to 40% by weight of amino acids calculated with respect to the total weight of the dry composition, wherein the content of essential amino acids present in the composition is from 2 to 25% by weight.
- the essential amino acids that are present in the composition include: leucine, isoleucine, valine, methionine, lysine, phenylalanine, tryptophan, threonine, histidine, and mixtures thereof.
- the essential amino acids: leucine and methionine are present in the composition in controlled amounts.
- Non-essential amino acids that may be present in the composition are selected from the group consisting of asparagine, alanine, arginine, aspartic acid, cysteine/cystine, glutamic acid, glutamine, proline, glycine, tyrosine, serine, and mixtures thereof.
- amino acids such as betaine, taurine, etc.
- betaine amino acid metabolites and/or precursors thereof.
- compositions according to the present invention comprise ⁇ 10% by weight of leucine and ⁇ 0.6% by weight of methionine with respect to the total weight of the dry composition.
- compositions according to the present invention comprise leucine in an amount of from 0.5-6% by weight and methionine in an amount of between 0.1 to 0.6% by weight with respect to the total weight of the dry composition. .
- glutamine in addition to leucine in an amount of between 0.5 to 6% by weight and methionine in an amount of between 0.1 to 0.6% by weight, glutamine is present. in an amount of 0 to 10% and the cysteine/cystine is present in an amount of 0 to 0.5% by weight relative to the total weight of the dry composition.
- Preferred amounts of leucine in the composition are: 0.5%, 2.5%; 5%, 6% and 10% by weight with respect to the total weight of the dry composition.
- Preferred amounts of methionine in the composition are: 0.17%; 0.5% and 0.6% by weight with respect to the total weight of the dry composition.
- the preferred amounts of glutamine in the composition are: 1.3%, 5% and 6% by weight with respect to the total weight of the dry composition.
- the preferred amounts of cysteine/cystine in the composition are: 0%, 0.2% and 0.5% by weight with respect to the total weight of the dry composition.
- the amino acids present in the dietary composition of the present invention may be amino acids in free form, salts, ester and/or in the form of an amino acid source, such as a polypeptide, a peptide, a protein, a metabolite and/or amino acid precursor.
- an amino acid source such as a polypeptide, a peptide, a protein, a metabolite and/or amino acid precursor.
- the proteins present in the composition as a source of amino acids can be selected from the group consisting of: casein, and any other protein that provides the levels of amino acids described in the present invention, such as collagen, albumin, globulin, ovalbumin, zein, fibroma , keratin, gelatin, gluten, whey protein, egg protein, pea protein, hemp protein, soy protein, and vegetable and animal protein isolates.
- the composition of the present invention comprises casein as an amino acid source, alone or in combination with additional amino acids in free form, salts or esters.
- amino acids in free, salt or ester form are commercially available from, for example, Applichem, Acros Organics, ProFoods, BulkSupplements.com, Blackburn Distributions, Myprotein, etc.
- composition of the present invention comprises, in addition to amino acids, as discussed in the preceding paragraphs, one or more lipid ingredients in an amount of from 0 to 25% by weight with respect to the total weight of the dry composition.
- the one or more lipid ingredients are present in an amount of between 0 to 14% by weight with respect to the total weight of the dry composition.
- Lipid ingredients suitable for the purpose of the compositions of the present invention may be selected from any edible vegetable or animal oil, such as rapeseed oil, sunflower oil, corn oil, soybean oil, linseed oil, rice, safflower oil, olive oil, coconut oil, cottonseed oil, fish oil and the like.
- the lipid ingredient is selected from the group consisting of: olive oil, coconut oil, salmon oil, and mixtures thereof.
- Such lipid ingredients are commercially available, for example from local markets.
- the composition of the present invention comprises, in addition to amino acids and lipids, as defined in any of the previous paragraphs, one or more carbohydrates in an amount of from 40 to 95% by weight with respect to the total weight of the dry composition.
- the carbohydrate portion of the composition may be supplied by any suitable carbohydrate source, for example, starches, dextrins, glycogen, glucose, fructose, sugars, monosaccharides, disaccharides, oligosaccharides, polysaccharides, and mixtures thereof.
- Preferred carbohydrates according to the present invention may be selected from the group consisting of: sucrose, cellulose, and starch, and mixtures thereof.
- Such carbohydrates are commercially available from, for example, local markets, ProFoods, BulkSupplements.com, Blackburn Distributions, Myprotein, etc.
- composition of the present invention comprises, in addition to amino acids, lipids and carbohydrates, as defined in any of the previous paragraphs, a mixture of vitamins and minerals in an amount of from 1 to 5% by weight with respect to the total weight. of the dry composition.
- Suitable mixtures of vitamins and minerals to be used in the compositions of the present invention can be selected from the group consisting of: calcium carbonate, potassium monophosphate, potassium citrate, sodium chloride, potassium sulfate, magnesium oxide , ferric citrate, zinc carbonate, manganese carbonate, copper carbonate, potassium iodate, sodium selenate, ammonium paramolybdate tetrahydrate, sodium metasilicate nonahydrate, potassium chromium sulfate dodecahydrate, lithium chloride, boric acid , sodium fluoride, nickel carbonate hydroxide, ammonium meta-vanadate, thiamine hydrochloride, riboflavin, pyridoxine hydrochloride, nicotinic acid, calcium D-pantothenate, folic acid, D-biotin, cyanocobalamin (vitamin B12), premix retinyl palmitate (vitamin A) (250,000 IU/g), DL-a-tocopherol acetate (
- the composition additionally comprises choline in free form, salts, ester, such as choline chloride or choline bitartrate, in an amount of from 0 to 1%, preferably 0.25% by weight with respect to the total weight of the dry composition.
- choline in free form, salts, ester, such as choline chloride or choline bitartrate, in an amount of from 0 to 1%, preferably 0.25% by weight with respect to the total weight of the dry composition.
- Such vitamin and mineral mixtures are commercially available, for example, from Fisher Bioreagents, MP biomedical, etc.
- the dietary compositions of the present invention may additionally contain optional ingredients selected from the group consisting of: stabilizers, preservatives, emulsifiers, and flavoring agents, as commonly known from “Formulation Engineering of Foods”, Wiley-Blackwell, August 2013 and “Handbook of Food Chemistry” Springer, 2015.
- the dietary product of the present invention is suitable for oral administration and will therefore be in any liquid to solid form with corresponding consistencies and viscosities to meet swallowing needs, such as clear liquid, soft or full solid diet.
- suitable forms include: powder, shake, liquid concentrates, ready-to-drink beverage, cold or shelf-stable beverage, soup, paste, puree, nutrition bar, etc.
- composition of the present invention may optionally comprise, in addition to any of the aforementioned ingredients, water or water-based vehicles to form the artificial diet of the present invention.
- Water or any water-based carrier can be mixed with the composition ingredients listed in the preceding paragraphs, as required, to form the artificial diet composition of the present invention of the desired consistency.
- the artificial diet composition of the present invention is present in the form of different consistencies and viscosities depending on the amount of water or water-based vehicle added in the composition so as to treat the health conditions of the subject that compromise the oral intake of the composition, such as, for example, dysphagia.
- the different consistencies and viscosities range from fluid to semi-solid and solid forms, with viscosities ranging from 0.001 to 0.05 Pa.s for fine liquids, range 0.051 to 0.35 Pa.s for nectar-type liquids, 0.351 to 1 0.75 Pa.s for honey-type liquids and not less than 1.751 Pa.s for liquids so dense that they can be taken with a spoon.
- composition of the present invention does not contain water or water-based carriers, so that the composition is present in a dry solid to semi-solid form.
- the dry solid or semi-solid composition is ready for consumption.
- said composition can be mixed with water prior to consumption to achieve the desired volume of the final artificial diet in liquid form.
- compositions comprising the dietary composition of the present invention as defined in any of the preceding paragraphs and in the claims together with pharmaceutically acceptable carriers, excipients or diluents.
- pharmaceutical compositions are formulated to be administered to a patient orally, enterally, rectally, vaginally, parenterally, intrapulmonarily, sublingually, pulmonaryly and/or intranasally.
- the present invention therefore preferably relates to a pharmaceutical formulation, wherein the formulation is in the form of a solid or liquid; and wherein the formulation is in the form of a tablet, a capsule, a gelatin tablet, a lozenge, an orally dissolved strip, syrup, an oral suspension, an emulsion, a granule, a spray and a pellet.
- a pharmaceutical formulation wherein the formulation is in the form of a solid or liquid; and wherein the formulation is in the form of a tablet, a capsule, a gelatin tablet, a lozenge, an orally dissolved strip, syrup, an oral suspension, an emulsion, a granule, a spray and a pellet.
- compositions are well known to one skilled in the art, see Remington, The Science and Practice of Pharmacy, 21st Edition; Lippincott Williams & Wilkins and Handbook of Pharmaceutical Excipients, 5th Edition, Rowe et al.
- the artificial diet composition of the present invention provides all of the daily nutritional requirements of a subject and is to be taken as a meal replacement. To meet the daily nutritional requirements of the subject, the artificial diet composition of the present invention may be taken once, twice, or in multiple doses as required to complete the daily caloric intake requirement. In a preferred embodiment, the artificial diet is taken in 4 to 6 target doses.
- the artificial diet composition of the present invention provides an enhanced antineoplastic effect when compared to therapeutic treatment with conventional drugs, such as sunitinib, anti-PD1, capecitabine or cisplatin.
- conventional drugs such as sunitinib, anti-PD1, capecitabine or cisplatin.
- the artificial diet composition of the invention is suitable for use as the sole active agent in the treatment of cancer.
- the artificial diet composition or the pharmaceutical composition comprising the artificial diet of the present invention is suitable for use in the treatment of cancer in a co-administration schedule with other antineoplastic drugs, said treatment schedule comprising sequential administration, concomitant or simultaneous active ingredients.
- Antineoplastic drugs contemplated to be used in combination with the artificial diet composition or the pharmaceutical composition comprising the artificial diet of the present invention are selected from the group comprising: cytotoxic chemotherapy drugs such as alkylating agents (eg, cisplatin , carboplatin, oxaliplatin, cyclophosphamide, temozolomide, hydroxyurea, etc.), antimetabolites (eg, fluorouracil, capecitabine, gemcitabine, methotrexate, cytarabine, etc.), mitotic inhibitors (eg, paclitaxel, docetaxel, cabazitaxel, vincristine, vinblastine, vinorelbine, vindesine, etc.), topoisomerase inhibitors (for example, etoposide, teniposide, irinotecan, topotecan, doxorubicins, epirubicin, etc.), hormonal therapy (for example, antiestrogens such as tamoxifen
- the dietary compositions of the present invention can be taken for about two to twelve weeks, once or several times depending on the course of the disease. After 2-12 weeks treatment with the metabolic diet, the patient returns to a normal diet for a predetermined period, such as one, two, three, etc., weeks.
- the daily doses contemplated to provide the desired therapeutic effect are those that provide the required caloric needs for the individual.
- calorie is commonly used as shorthand for kilocalorie (kcal), and that a person's calorie needs depend on age, gender, height, weight, and physical activity.
- the calories (kcal) provided by a metabolic diet can be estimated considering that 1 g of carbohydrates provides 4.1 calories (kcal), 1 g of protein (or amino acids) provides 4.1 calories, 1 g of fat (lipids ) provides 8.8 calories and 1 g of fiber provides 1.9 calories.
- the caloric needs for a person with the following characteristics male, 50 years old, 175 cm, 75 kg, little or no exercise) is approximately 1900 (https://www.calculator.net/bmr-calculator.html) . If this person is treated with the P9 diet, they would need to take approximately 500 g of the dry composition each day (500 g of this diet provides about 1900 calories).
- This total daily amount can be divided into 4-6 servings per day; for example, 100 g at 8:00 a.m., 100 g at 12:00 p.m., 100 g at 4:00 p.m., 100 g at 8:00 p.m., and 100 g at 12:00 p.m. Note that during treatment, the patient should only take these amounts of the dry compositions (which can be prepared with different amounts of water) and should only drink water. Cancer treatment:
- the present invention provides an artificial diet composition and/or a pharmaceutical composition for use in a method of treating cancer.
- the present invention also provides a method of treating cancer in a subject in need thereof, comprising administering to the subject in need thereof an effective amount of the dietary composition and/or the pharmaceutical composition of the present invention.
- Cancer treatment according to the present invention comprises any type of cancer, including kidney cancer, lung cancer, colon cancer, breast cancer, melanoma, ovarian cancer, prostate cancer, pancreatic cancer, liver cancer, endometrial cancer , cervical cancer, bladder cancer, esophageal cancer, gastric cancer, head and neck cancers, leukemia, lymphomas, nonmelanoma skin cancers, sarcomas, central nervous system cancers, testicular cancer, thyroid cancer, cancer of the unknown primary site, etc.
- cancer including kidney cancer, lung cancer, colon cancer, breast cancer, melanoma, ovarian cancer, prostate cancer, pancreatic cancer, liver cancer, endometrial cancer , cervical cancer, bladder cancer, esophageal cancer, gastric cancer, head and neck cancers, leukemia, lymphomas, nonmelanoma skin cancers, sarcomas, central nervous system cancers, testicular cancer, thyroid cancer, cancer of the unknown primary site, etc.
- the diets were prepared by mixing all the solid ingredients shown in the tables at room temperature according to well-known methods until they formed a well-mixed dry powder in a semi-solid to solid state depending on the amount of lipid ingredients used in each case.
- the mineral mix (Harlan Laboratories, AIN-93M-MX) constituted 3.5 % of the dry diet; 100 g of the dry diet contained 1.25% calcium carbonate, 0.875% potassium monophosphate, 0.098% potassium citrate, 0.259% sodium chloride, 0.163% potassium sulfate, 0.085% magnesium oxide, 0.021 % Ferric Citrate, 0.0058% Zinc Carbonate, 0.0022% Manganese Carbonate, 0.0011% Copper Carbonate, 0.000035% Potassium Iodate, 0.000035% Sodium Selenate, 0.000028% Ammonium Paramolybdate Tetrahydrate, 0.0051% Sodium Metasilicate Nonahydrate, 0.00095% Potassium Chromium Sulfate Dodecahydrate, 0.0000595% Lithium Chloride, 0.000284% Acid boric acid, 0.00022% sodium fluoride, 0.00011% nickel carbonate hydroxide, 0.000021% ammonium meta-vanadate, and 0.73% sucrose.
- the vitamin mixture (AIN Vitamin Mixture 76) constituted 1% of the dry diet; 100 g of the dry diet contained (mg) thiamine hydrochloride (0.6), riboflavin (0.6), pyridoxine hydrochloride (0.7), nicotinic acid (3), D-calcium pantothenate (1.6 ), folic acid (0.2), D-biotin (0.02), cyanocobalamin (vitamin B12) (0.001), retinyl palmitate premix (vitamin A) (250,000 IU/g) (1.6), acetate of DL-a-tocopherol (250 Ul/g) (20), cholecalciferol (vitamin D3, 400,000 Ul/g) (0.25), menaquinone (vitamin K2) (0.005), sucrose (972.9).
- thiamine hydrochloride 0.6
- riboflavin 0.6
- pyridoxine hydrochloride 0.7
- nicotinic acid (3) D-calcium pantothen
- Casein was obtained from Acras Organics. Amino acids were obtained from different sources, including Applichem, Acras Organics and Myprotein. Choline (bitartrate) was obtained from Acras Organics, olive oil, coconut oil and sucrose from local markets. Corn starch and cellulose were obtained from Farmusal (pharmacy local).
- Table 1 Preferred compositions.
- the typical amount (g) of amino acids in 100 g and 6 g (shown in parentheses) of the casein used in the experiments is: Glutamine + glutamate: 21.7 (1.302), leucine: 9 (0.54), methionine : 2.9 (0.174), phenylalanine: 4.8 (0.288), histidine: 2.6 (0.156), lysine: 7.5 (0.45), threonine: 4.1 (0.246), isoleucine: 4, 3 5 (0.258), valine: 5.3 (0.318), tryptophan: 1.2 (0.072), cysteine/cystine: 0.7 (0.042), arginine: 3.4 (0.204), glycine: 1.7 ( 0.102), serine: 5.7 (0.342), tyrosine: 5.2 (0.312), alanine: 2.9 (0.174), aspartate + asparagine: 6.9 (0.414), proline: 10.1 (0.606).
- Cell line A549 human non-small cell lung cancer
- ECACC European Collection of Authenticated Cell Cultures
- 786-0 kidney cancer
- MDA-MB-231 triple negative breast cancer
- LLc1 murine lung cancer
- Renca murine kidney cancer
- 4T1 murine breast cancer
- CT26WT colonal cancer
- A64-CLS adenoma of the submandibular glands
- AN3Ca endometrial adenocarcinoma
- BT-474 breast cancer
- luminal B ER+; PR+; Her-2 +
- Calu-1 squamous lung cancer
- HNO97 cancer of the tongue
- MeWo melanoma
- BRAF WT NIH:OVCAR-3
- Sk-Br-3 cancer of the breast; HER-2 +
- Sk-OV-3 cancer of ovary
- T24 cancer
- T-47D breast cancer
- luminal A ER+; PR+; Her-2 -
- CLS Cell Lines Service
- UACC-62 melanoma; melanoma; BRAF mut
- CAPAN-1 pancreatic cancer
- HepG2 human hepatocellular carcinoma
- HT29 colonrectal cancer
- PC3 human prostate cancer
- GAMG glioblastoma
- Dr. Ayala Universality of Seville, Spain
- DMEM Dulbecco's modified Eagle's medium
- 4T1, 786-0 Calu-1, CAPAN-1, CT26WT, NIH:0VCAR-3, PC-3, Renca, T-47D, UACC-62 in RPMI 1640.
- Exponentially growing cells were seeded in 96-well plates and allowed to grow for 24 h. The cells were then exposed to the artificial media or to various concentrations of the antineoplastic drugs for 7 days. The cells were then allowed to recover in their corresponding conventional medium (without drug) for 3 days. Cell viability was then estimated with the resazurin assay.
- This assay is a redox-based colorimetric technique based on the ability of viable cells to reduce the blue reagent resazurin to a pink product. The number of living cells is directly proportional to the amount of final product formed.
- mice All mice were purchased from Janvier Labs® (France). Male BALB/cAnNRJ mice were used for the kidney cancer model (Renca cells, intraperitoneal model). Female BALB/cAnNRJ mice were used for the colon cancer models (CT26WT cells, intraperitoneal and intravenous models), and for the triple negative breast cancer model (4T1 cells, intravenous model). Female C57BL/6J mice were used for the lung cancer model (LLc1 cells, intravenous model) and for the melanoma model (B16-F10 cells, intravenous model). All mice were 12 weeks or older at the beginning of the experiments. Treatments started 8 days after injection of cancer cells for the 4T1 breast cancer model and for the Renca kidney cancer model.
- Treatments started 7 days after injection for the Renca cancer model when the number of cells inoculated was 150,000, and for the LLc1 lung cancer model. Treatments started 4 days after injection in the CT26WT (intraperitoneal and intravenous) colon cancer models and in the B16-F10 melanoma model.
- Murine cells (passage 5°-7°) were cultured in a 75 cm 2 culture flask. When the cells were approximately 60-70% confluent, the medium was removed and the cells were washed twice with sterile PBS. Then, the cells were incubated with trypsin/EDTA solution for 2-3 min at 37°C to allow the cells to have a round shape, but without detachment. The trypsin/EDTA solution was then aspirated, the cells resuspended in 5 mL sterile PBS, and the cell suspension pipetted up and down to break up any cell aggregates before medium supplemented with 10% FBS was added.
- a working cell suspension (between 5x10 5 - 25x10 6 cells/ml depending on the cancer model) was prepared. This suspension was centrifuged (5 min, 250 g) at room temperature. Media was removed and cells were resuspended in media supplemented with 2.5% warm FBS. The working cell suspension was aliquoted into 2 mL tubes and kept at 37 °C in a humidified atmosphere containing 5% CO2 until use. Several minutes before injection, the tubes were centrifuged at 300 g at 4 °C for 3 min, the medium was removed, and the cells were resuspended in sterile PBS. The cells were counted again.
- a 1 mL syringe (insulin type with a 29-G x 1/2" needle) was filled with 0.2 mL of the working cell suspension, which was injected into the peritoneal cavity or intravenous vein.
- tail of mice After inoculating the last mice, the cells in the last tube were placed in a culture flask and monitored for several weeks under the microscope to ensure that all mice were inoculated with viable cells.
- mice were housed in individual cages to avoid cannibalism.
- the treatments began four, seven or eight days (depending on the model) after the cancer cells were injected.
- Most of the treatments with the artificial diets lasted at least 4 weeks.
- the treatment with the artificial diets consisted simply of substituting their normal diet with an artificial diet in which the levels of AA and specific lipids were manipulated.
- Sunitinib and capecitabine were administered daily in the diet.
- Cisplatin and anti-PD1 antibody were injected intraperitoneally. The animals were monitored daily and body weights determined periodically (at least three times per week). Mice were sacrificed by cervical dislocation.
- Diets were prepared by first mixing all the solid ingredients shown in the tables until they formed a well mixed dry powder. After the oil (if present in the composition) was added to the mixture, enough water was added a little at a time to make a soft dough. The dough was allowed to air-dry for approximately 2 h, hand-pelletized (approximately 5 g/pellet), air-dry for an additional 2 h and stored until use.
- the mineral mixture (Harán Laboratories, AIN-93M-MX) constituted 3.5 % of the dry diet; 100 g of the dry diet contained 1.25% calcium carbonate, 0.875% potassium monophosphate, 0.098% potassium citrate, 0.259% sodium chloride, 0.163% potassium sulfate, 0.085% magnesium oxide, 0.021 % Ferric Citrate, 0.0058% Zinc Carbonate, 0.0022% Manganese Carbonate, 0.0011% Copper Carbonate, 0.000035% Potassium Iodate, 0.000035% Sodium Selenate, 0.000028% Ammonium Paramolybdate Tetrahydrate, 0.0051% Sodium Metasilicate Nonahydrate, 0.00095% Potassium Chromium Sulfate Dodecahydrate, 0.0000595% Lithium Chloride, 0.000284% Acid boric acid, 0.00022% sodium fluoride, 0.00011% nickel carbonate hydroxide, 0.000021% ammonium meta-vanadate, and 0.73% sucrose.
- the vitamin mixture (AIN Vitamin Mixture 76, Fisher Bioreagents) constituted 1% of the dry diet; 100 g of the dry diet contained (mg) thiamine hydrochloride (0.6), riboflavin (0.6), pyridoxine hydrochloride (0.7), nicotinic acid (3), calcium D-pantothenate (1.6 ), folic acid (0.2), D-biotin (0.02), cyanocobalamin (vitamin b12) (0.001), retinyl palmitate premix (vitamin a) (250,000 IU/g) (1.6), acetate of DL-a-tocopherol (250 Ul/g) (20), cholecalciferol (vitamin D3, 400,000 Ul/g) (0.25), menaquinone (vitamin K2) (0.005), sucrose (972.9).
- thiamine hydrochloride 0.6
- riboflavin 0.6
- pyridoxine hydrochloride 0.7
- nicotinic acid (3) calcium
- Casein was obtained from Acras Organics (27607; bovine).
- the typical amount (g) of amino acids in 100 g and 6 g (shown in parentheses) of the casein used in the experiments is: Glutamine + glutamate: 21.7 (1.302), leucine: 9 (0.54), methionine : 2.9 (0.174), phenylalanine: 4.8 (0.288), histidine: 2.6 (0.156), lysine: 7.5 (0.45), threonine: 4.1 (0.246), isoleucine: 4, 3 (0.258), valine: 5.3 (0.318), tryptophan: 1.2 (0.072), cysteine/cystine: 0.7 (0.042), arginine: 3.4 (0.204), glycine: 1.7 (0.102), serine: 5.7 (0.342), tyrosine: 5.2 (0.312), alanine: 2 .9 (0.174), aspartate + asparagine: 6.9 (0.414),
- the amino acids were obtained from different sources, including Applichem, Acros Organics and Myprotein. Choline (bitartrate) was obtained from Acros Organics, olive oil, coconut oil and sucrose were obtained from local markets. Salmon oil was obtained from Petspurest. Corn starch and cellulose were obtained from Farmusal (local pharmacy).
- Sunitinib malate (462640010, Acros Organics) was mixed into the food. Mice were fed a standard diet supplemented with sunitinib (350 mg/kg diet) for 28 days. A 25 g mouse normally consumed an average of 4.5 g of diet per day, resulting in a dose of approximately 60 mg/kg/day. The normal diet was pulverized and mixed with sunitinib. Sufficient water was then added to prepare a soft dough, which was allowed to air-dry for approximately 2 h, manually pelleted (approximately 5 g/pellet) and stored until use. Capecitabine (500 mg/tablet, 707278.2, Normon) was also mixed in the food (following the process described for sunitinib).
- mice were fed a conventional diet supplemented with capecitabine (2500 mg/kg diet) for 7 days, followed by normal drug-free food for 7 days. The mice received two to three cycles depending on their health status. A 25 g mouse normally consumed an average of 4.5 g of diet per day, resulting in a dose of approximately 450 mg/kg/day.
- Cisplatin (1 mg/ml, 659219.9, Cisplatin Pharmacia, Pfizer) was administered intraperitoneally once a week for 4 weeks. Mice received a dose of 5 mg/kg at each dose.
- Anti-PD-1 (mouse anti-PD-1 (CD279), clone RMP1-14, BE0146, Bioxcell) was administered intraperitoneally every 4 days for a total of 4 doses. At each dose, mice received 250 pg. Anti-PD-1 was diluted in pH 7.0 buffer (InVivoPure, IP0070, Bioxcell). In in vitro experiments, the present inventors also used the following antineoplastic drugs: Doxorubicin (50 mg powder for solution, 958314.9, Farmiblastin, Pfizer), 5-fluorouracil (F6627, sigma), and paclitaxel (66997, TEVA, 6 mg/ ml).
- Table 3 shows the results of an experiment in mice with kidney cancer treated with various diets. In most diets, one amino acid was added or removed relative to diet P2. Previous amino acid restricted diets (e.g. WO 2017/144877) indicated that the activity of the diets depends on the removal of one or more amino acids such as serine and glycine. This experiment clearly shows that removal of serine is not required for activity; indeed, mice treated with the serine-containing diet (P13) live longer than mice treated with the serine-free diet (P2).
- mice with kidney cancer treated with various metabolic diets Male BALB/cAnNRJ mice with renal cell carcinoma were treated with anti-PD1 antibody (250 pg administered intraperitoneally on days 8, 12, 16 and 20), with one of the following diets: P2, P3, P13, P14 , P15, P16, P17, P18, P19, P20, P21 (normal diet was substituted for one of these diets for 28 days), or left untreated (control, normal diet). Treatments began 8 days after intraperitoneal injection of 100,000 Renca cancer cells. At least three mice were included in each group.
- mice were sacrificed by cervical dislocation when signs of disease progression were evident; these signs (eg, excessive gains and losses in body weights, reduced mobility and curiosity, and/or visible or palpable tumors larger than 15-20 mm) indicated that survival for an additional 48 h was unlikely. Cadaveric examination confirmed the presence of tumors in all sacrificed mice.
- the anti-PD1 antibody (nivolumab) is a first-line drug for patients with metastatic kidney cancer.
- the levels of the amino acid methionine are less than or equal to 0.6%.
- the results shown in Table 4 indicate that the amount of methionine should not be more than 0.6% to achieve antineoplastic activity in mice with cancer.
- the P22 diet (containing only the methionine provided by casein, i.e. 0.17%), however, showed marked antitumor activity, even higher than that observed in mice treated with sunitinib (a first-line treatment for patients with metastatic kidney cancer).
- mice with kidney cancer treated with various metabolic diets Male BALB/cAnNRJ mice with renal cell carcinoma were treated with sunitinib (60 mg/kg/day, 28 days, orally), on one of the following diets: P22, P23, P24, P11, P9 (substituted the normal diet by one of these diets for 28 days), or left untreated (control, normal diet). Treatments began 7 days after intraperitoneal injection of 150,000 Renca cancer cells. Mice that survived the 28-day treatment (with diets and sunitinib) were put on a normal diet for 10 days and then returned to treatment (diet or sunitinib) for an additional 21 days (up to day 66 after cell inoculation). cancerous).
- mice included at least four mice in each group. Mice were sacrificed by cervical dislocation when signs of disease progression were evident; these signs (eg, excessive gains and losses in body weights, reduced mobility and curiosity, and/or visible or palpable tumors exceeding 15-20 mm) indicated that survival for an additional 48 h was unlikely. Cadaveric examination confirmed the presence of tumors in all sacrificed mice.
- Sunitinib is a first-line drug for patients with metastatic kidney cancer.
- the levels of the amino acid leucine are less than or equal to 10%.
- diet P11 containing only the leucine provided by casein, i.e. 0.54%
- diet P9 containing 3.04% leucine (2.5 pure leucine + 0.54 of the leucine contained in 6 g of casein) showed a marked antitumor effect (more than 23.75 days longer than untreated mice; one mouse is still alive and without any signs of disease).
- the antineoplastic activity of this diet (P9) was higher than that observed in mice treated with sunitinib (a first-line treatment for patients with metastatic kidney cancer), which was 17.25 days.
- mice with colon cancer the P10 diet (containing 3.04% leucine; 2.5% pure leucine + 0.54% leucine contained in 6g casein) was much more active than the P10 diet.
- P11 containing only the leucine provided by casein, i.e. 0.54%.
- BALB/cAnNRJ mice with colon cancer were treated with diet P10 (6 weeks), with diet P11 (6 weeks), with capecitabine (450 mg/kg/day, treatment 7 days + rest 7 days, to excessive toxicity or death, oral administration), or left untreated (control). At least three mice were included in each group.
- Treatments began 4 days after intraperitoneal injection of 100,000 CT26.WT cancer cells. Mice were sacrificed by cervical dislocation when signs of disease progression were evident; these signs (eg, excessive gains and losses in body weights, reduced mobility and curiosity, and/or visible or palpable tumors exceeding 15-20 mm) indicated that survival for an additional 48 h was unlikely. Cadaveric examination confirmed the presence of tumors in all sacrificed mice.
- mice treated with capecitabine (a first treatment line for patients with metastatic colon cancer) lived 4.5 days longer than untreated mice, mice treated with diet P11 (0.54% leucine) lived 2.3 days longer than untreated mice, and mice treated with the P10 diet (3.04% leucine) lived >44.1 days longer than untreated mice (2 of the 7 mice used in this group are alive and without any signs of disease).
- mice returned to their normal diet (rich in protein and fat), and the weights after 10 days (day 45) decreased to 24.2 g and 27.0 g.
- the P22 diet was then restarted and 10 days later (day 55) the weights increased to 28.0 g and 30.4 g.
- Mice died on day 63 and 83 (P22 treatment ended on day 66).
- Table 5 shows the survival improvements achieved with a variety of metabolic diets in mice with various types of cancer relative to mice receiving no treatment (control). Survival improvements achieved with drugs used in cancer patients are also shown.
- Table 5 Antineoplastic activity of a variety of diets and various antineoplastic drugs in mice with different types of cancer.
- the compositions of the diet (P1-P24) are shown in Tables 1 and 2.
- the experimental conditions are described in the section "Mice and experimental conditions in vivo".
- the sign > indicates that one or more mice that received the treatment are still alive
- the * sign indicates that the results are represented in Figures 1-4.
- FIG. 1 shows the survival of male BALB/cAnNRJ mice with renal cell carcinoma treated with sunitinib (60 mg/kg/day, 28 days, administered orally), with anti-PD1 antibody (250 pg administered intraperitoneally in on days 8, 12, 16, and 20), on diet P2 (28 days; normal diet was substituted for diet P2), or left untreated (control, normal diet). Treatments began 8 days after intraperitoneal injection of 100,000 lame cancer cells.
- mice were sacrificed by cervical dislocation when signs of disease progression were evident; these signs (eg, excessive gains and losses in body weights, reduced mobility and curiosity, and/or visible or palpable tumors exceeding 15-20 mm) indicated that survival for an additional 48 h was unlikely.
- Sunitinib and the anti-PD1 antibody are first-line drugs for patients with metastatic kidney cancer.
- Figure 2 shows the survival of female BALB/cAnNRJ mice with colon cancer treated with capecitabine (450 mg/kg/day, 7-day treatment + 7-day rest, until excessive toxicity or death, oral administration), with diet P10 (6 weeks), or left untreated (control). Treatments began 4 days after intraperitoneal injection of 100,000 CT26.WT cancer cells. Mice were sacrificed by cervical dislocation when signs of disease progression were evident; these signs (eg, excessive gains and losses in body weights, reduced mobility and curiosity, and/or visible or palpable tumors exceeding 15-20 mm) indicated that survival for an additional 48 h was unlikely. Cadaveric examination confirmed the presence of tumors in all sacrificed mice.
- FIG. 3 shows the survival of female BALB/cAnNRJ mice with colon cancer treated with capecitabine (450 mg/kg/day, 7-day treatment + 7-day rest until excessive toxicity or death, oral administration), with the diet P6 (28 days), or left untreated (control). Treatments began 4 days after tail vein injection of 100,000 CT26.WT cancer cells. Mice were sacrificed by cervical dislocation when signs of disease progression were evident; these signs (eg, respiratory failure, excessive gains and losses in body weights, reduced mobility and curiosity, and/or visible or palpable tumors exceeding 15-20 mm) indicated that survival for an additional 48 h was unlikely.
- Figure 4 shows survival of female BALB/cAnNRJ mice with triple negative breast cancer treated with capecitabine (450 mg/kg/day, 7-day treatment + 7-day rest until excessive toxicity or death, oral administration), with cisplatin (5 mg/kg weekly for 4 weeks, intraperitoneal injection), on diet P6 (28 days), on diet P8 (28 days), or left untreated (control). Treatments began 8 days after tail vein injection of 100,000 4T1 cancer cells. Mice were sacrificed by cervical dislocation when signs of disease progression were evident; these signs (eg, respiratory failure, excessive gains and losses in body weights, reduced mobility and curiosity, and/or visible or palpable tumors exceeding 15-20 mm) indicated that survival for an additional 48 h was unlikely.
- capecitabine 450 mg/kg/day, 7-day treatment + 7-day rest until excessive toxicity or death, oral administration
- cisplatin 5 mg/kg weekly for 4 weeks, intraperitoneal injection
- mice were sacrificed by cervical dislocation when signs of disease progression were evident; these signs
- Capecitabine a prodrug of 5-fluorouracil
- Cisplatin is a widely used drug in many types of cancer.
- Cell culture medium M1 (equivalent to diet P1), M2 (equivalent to diet P2) and M3 (equivalent to diet P3) were prepared to assess their cytotoxicity and selectivity towards cancer cells.
- M0 medium containing all amino acids, was also prepared and tested under the same experimental conditions.
- the composition of the media is shown in Table 6. These media were tested on human normal skin cells with high proliferation rates (HaCaT) and on 20 human cancer cell types representing the most common cancer types.
- HaCaT high proliferation rates
- Four commonly used anticancer drugs (representing the main types of chemotherapy) were also tested on the 21 human cell lines to compare the selective anticancer activity of amino acid-restricted media with that of standard anticancer drugs.
- Kantarjian H Stewart DJ, Zwelling L. Cancer research in the United States: dying by a thousand paper cuts. Cancer. 2013; 119(21): 3742-3745.
- Kantarjian H Zwelling L. Cancer drug prices and the free-market forces. Cancer. 2013; 119(22): 3903-3905.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2023002039A MX2023002039A (es) | 2020-09-23 | 2020-09-23 | Terapia metabolica del cancer. |
AU2020468941A AU2020468941A1 (en) | 2020-09-23 | 2020-09-23 | Metabolic cancer therapy |
CA3192176A CA3192176A1 (en) | 2020-09-23 | 2020-09-23 | Metabolic therapy of cancer |
PCT/ES2020/070571 WO2022064079A1 (es) | 2020-09-23 | 2020-09-23 | Terapia metabólica del cáncer |
KR1020237008899A KR20230098562A (ko) | 2020-09-23 | 2020-09-23 | 암의 대사 요법 |
JP2023517757A JP2023544981A (ja) | 2020-09-23 | 2020-09-23 | 癌の代謝療法 |
CN202080104980.3A CN116096251A (zh) | 2020-09-23 | 2020-09-23 | 癌症的代谢疗法 |
US18/025,229 US20230329304A1 (en) | 2020-09-23 | 2020-09-23 | Metabolic therapy of cancer |
EP20800703.9A EP4190173A1 (en) | 2020-09-23 | 2020-09-23 | Metabolic cancer therapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2020/070571 WO2022064079A1 (es) | 2020-09-23 | 2020-09-23 | Terapia metabólica del cáncer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022064079A1 true WO2022064079A1 (es) | 2022-03-31 |
Family
ID=73043291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2020/070571 WO2022064079A1 (es) | 2020-09-23 | 2020-09-23 | Terapia metabólica del cáncer |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230329304A1 (es) |
EP (1) | EP4190173A1 (es) |
JP (1) | JP2023544981A (es) |
KR (1) | KR20230098562A (es) |
CN (1) | CN116096251A (es) |
AU (1) | AU2020468941A1 (es) |
CA (1) | CA3192176A1 (es) |
MX (1) | MX2023002039A (es) |
WO (1) | WO2022064079A1 (es) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030129262A1 (en) * | 2001-08-30 | 2003-07-10 | Epner Daniel E. | Methionine restriction for cancer therapy |
EP1572093A2 (en) | 2002-08-01 | 2005-09-14 | Aesgen, Inc. | Improved treatment of cancer with glutamine |
US20120082760A1 (en) * | 2010-10-01 | 2012-04-05 | Rosedale Ronald E | mTOR PATHWAY OPTIMIZED NUTRITIONAL COMPOSITIONS |
US20130330419A1 (en) | 2011-02-23 | 2013-12-12 | Dorit Arad | Compositions and methods for personal tumor profiling treatment |
US20140112909A1 (en) * | 2012-10-22 | 2014-04-24 | University Of Southern California | Methods and formulations promoting tissue/organ regeneration, longevity and healthspan |
WO2017053328A1 (en) | 2015-09-21 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nutritional treatment for cancer |
WO2017144877A1 (en) | 2016-02-23 | 2017-08-31 | Cancer Research Technology Limited | Dietary product devoid of at least two non essential amino acids |
-
2020
- 2020-09-23 AU AU2020468941A patent/AU2020468941A1/en active Pending
- 2020-09-23 MX MX2023002039A patent/MX2023002039A/es unknown
- 2020-09-23 CN CN202080104980.3A patent/CN116096251A/zh active Pending
- 2020-09-23 JP JP2023517757A patent/JP2023544981A/ja active Pending
- 2020-09-23 WO PCT/ES2020/070571 patent/WO2022064079A1/es unknown
- 2020-09-23 KR KR1020237008899A patent/KR20230098562A/ko active Search and Examination
- 2020-09-23 EP EP20800703.9A patent/EP4190173A1/en active Pending
- 2020-09-23 US US18/025,229 patent/US20230329304A1/en active Pending
- 2020-09-23 CA CA3192176A patent/CA3192176A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030129262A1 (en) * | 2001-08-30 | 2003-07-10 | Epner Daniel E. | Methionine restriction for cancer therapy |
EP1572093A2 (en) | 2002-08-01 | 2005-09-14 | Aesgen, Inc. | Improved treatment of cancer with glutamine |
US20120082760A1 (en) * | 2010-10-01 | 2012-04-05 | Rosedale Ronald E | mTOR PATHWAY OPTIMIZED NUTRITIONAL COMPOSITIONS |
US20130330419A1 (en) | 2011-02-23 | 2013-12-12 | Dorit Arad | Compositions and methods for personal tumor profiling treatment |
US20140112909A1 (en) * | 2012-10-22 | 2014-04-24 | University Of Southern California | Methods and formulations promoting tissue/organ regeneration, longevity and healthspan |
WO2017053328A1 (en) | 2015-09-21 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nutritional treatment for cancer |
WO2017144877A1 (en) | 2016-02-23 | 2017-08-31 | Cancer Research Technology Limited | Dietary product devoid of at least two non essential amino acids |
Non-Patent Citations (30)
Title |
---|
"Formulation Engineering of Foods", August 2013, WILEY-BLACKWELL |
BLAGOSKLONNY MV.: "Cancer stem cell and cáncer stemloids: from biology to therapy", CANCER BIOL THER, vol. 6, no. 11, 2007, pages 1684 - 1690 |
BOZZETTI FMARIANI L: "Defining and classifying cáncer cachexia: a proposal by the SCRINIO Working Group", JPEN J PARENTER ENTERAL NUTR, vol. 33, no. 4, 2009, pages 361 - 367 |
DEAN M.: "ABC transporters, drug resistance, and cáncer stem cells", J MAMMARY GLAND BIOL NEOPLASIA, vol. 14, no. 1, 2009, pages 3 - 9, XP019681547 |
DEAN MFOJO TBATES S.: "Tumour stem cells and drug resistance", NAT REV CANCER, vol. 5, no. 4, 2005, pages 275 - 284, XP055399679, DOI: 10.1038/nrc1590 |
FORBES SABEARE DGUNASEKARAN PLEUNG KBINDAL NBOUTSELAKIS HDING MBAMFORD SCOLE CWARD S: "COSMIC: exploring the world's knowledge of somatic mutations in human cáncer", NUCLEIC ACIDS RES., vol. 43, 2015, pages D805 - D811, XP055386484, DOI: 10.1093/nar/gku1075 |
GIBBS WW.: "Untangling the roots of cáncer", SCI AM., vol. 289, no. 1, 2003, pages 56 - 65 |
GORDON DJRESIO BPELLMAN D: "Causes and consequences of aneuploidy in cáncer", NAT REV GENET, vol. 13, no. 3, 2012, pages 189 - 203, XP055654691, DOI: 10.1038/nrg3123 |
GOTTESMAN MM: "Mechanisms of cáncer drug resistance", ANNU REV MED., vol. 53, 2002, pages 615 - 27, XP055349969, DOI: 10.1146/annurev.med.53.082901.103929 |
HALL MDHANDLEY MDGOTTESMAN MM: "Is resistance useless? Multidrug resistance and collateral sensitivity", TRENDS PHARMACOL SCI, vol. 30, no. 10, 2009, pages 546 - 556, XP026639902, DOI: 10.1016/j.tips.2009.07.003 |
HANAHAN D.: "Rethinking the war on cáncer", LANCET, vol. 383, no. 9916, 2014, pages 558 - 563 |
KAISER J.: "The cáncer stem cell gamble", SCIENCE, vol. 347, no. 6219, 2015, pages 226 - 229 |
KANTARJIAN HSTEWART DJZWELLING L.: "Cancer research in the United States: dying by a thousand paper cuts", CANCER, vol. 119, no. 21, 2013, pages 3742 - 3745 |
KANTARJIAN HZWELLING L: "Cancer drug prices and the free-market forces", CANCER, vol. 119, no. 22, 2013, pages 3903 - 3905 |
KERN KANORTON JA: "Cancer cachexia", JPEN J PARENTER ENTERAL NUTR, vol. 12, no. 3, 1988, pages 286 - 298 |
LOPEZ-LAZARO M.: "Cancer arises from stem cells: opportunities for anticancer drug discovery", DRUG DISCOV TODAY, 2015 |
LOPEZ-LAZARO M.: "Cancer etiology: Variation in cáncer risk among tissues is poorly explained by the number of gene mutations", GENES CHROMOSOMES CANCER, vol. 57, no. 6, June 2018 (2018-06-01), pages 281 - 293 |
LOPEZ-LAZARO M.: "The migration ability of stem cells can explain the existence of cáncer of unknown primary site. Rethinking metástasis", ONCOSCIENCE, vol. 2, no. 5, 2015, pages 467 - 475 |
LOPEZ-LAZARO M.: "The stem cell división theory of cáncer", CRIT REV ONCOL HEMATOL, vol. 123, 2018, pages 95 - 113 |
LOPEZ-LAZARO M: "Selective Amino Acid Restriction Therapy (SAART): a non-pharmacological strategy against all types of cáncer cells", ONCOSCIENCE, vol. 2, no. 10, 2015, pages 857 - 866 |
MCCARTHY DO: "Rethinking nutritional support for persons with cáncer cachexia", BIOL RES NURS, vol. 5, 2003, pages 3 - 17 |
MCGRANAHAN NSWANTON C.: "Biological and therapeutic impact of intratumor heterogeneity in cáncer evolution", CANCER CELL, vol. 27, no. 1, 2015, pages 15 - 26, XP029131336, DOI: 10.1016/j.ccell.2014.12.001 |
ROHRIG FSCHULZE A: "The multifaceted roles of fatty acid synthesis in cáncer", NAT REV CANCER, vol. 16, no. 11, 2016, pages 732 - 749 |
SCOTT LLAMB JSMITH SWHEATLEY DN: "Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells", BR J CANCER, vol. 83, no. 6, 2000, pages 800 - 810, XP055370750, DOI: 10.1054/bjoc.2000.1353 |
SIEGEL RLMILLER KDJEMAL A: "Cancer statistics", CA CANCER J CLIN, vol. 70, no. 1, 2020, pages 7 - 30 |
STEWART DJWHITNEY SNKURZROCK R.: "Equipoise lost: ethics, costs, and the regulation of cáncer clinical research", J CLIN ONCOL, vol. 28, no. 17, 2010, pages 2925 - 2935 |
STRATTON MR.: "Exploring the genomes of cáncer cells: progress and promise", SCIENCE, vol. 331, no. 6024, 2011, pages 1553 - 1558, XP055090618, DOI: 10.1126/science.1204040 |
TOYAMA BHHETZER MW.: "Protein homeostasis: live long, won't prosper", NAT REV MOL CELL BIOL, vol. 14, no. 1, 2013, pages 55 - 61 |
WEINBERG RA: "Coming full circle-from endless complexity to simplicity and back again", CELL, vol. 157, no. 1, 2014, pages 267 - 271, XP028601894, DOI: 10.1016/j.cell.2014.03.004 |
YEN HCXU QCHOU DMZHAO ZELLEDGE SJ: "Global protein stability profiling in mammalian cells", SCIENCE, vol. 322, no. 5903, 2008, pages 918 - 923, XP055295316, DOI: 10.1126/science.1160489 |
Also Published As
Publication number | Publication date |
---|---|
KR20230098562A (ko) | 2023-07-04 |
CA3192176A1 (en) | 2022-03-31 |
EP4190173A1 (en) | 2023-06-07 |
US20230329304A1 (en) | 2023-10-19 |
MX2023002039A (es) | 2023-03-15 |
JP2023544981A (ja) | 2023-10-26 |
CN116096251A (zh) | 2023-05-09 |
AU2020468941A1 (en) | 2023-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Anderson et al. | Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation | |
Nicolini et al. | Malnutrition, anorexia and cachexia in cancer patients: a mini-review on pathogenesis and treatment | |
JP4699901B2 (ja) | 体脂肪代謝機能と燃焼エネルギーの活用機能とを備えているダイエット用添加物質 | |
ES2338022T3 (es) | Potenciador del efecto antineoplasico. | |
JPH0534337B2 (es) | ||
Ajani et al. | A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma | |
TW200410680A (en) | Nutritiona compositions | |
Iwase et al. | Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial | |
JP2013508411A5 (es) | ||
US20190083439A1 (en) | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer | |
US11896569B2 (en) | Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy | |
ES2284660T3 (es) | Composicion que contiene un antiofolato y un agente que rebaja el acido metilmalonico. | |
NO336884B1 (no) | Glufosfamid og gemcitabin for behandling av kanser, og glufosfamid for behandling av kjemoterapi-motstandsdyktig bukspyttkjertelkanser. | |
RU2472354C1 (ru) | Биологически активная добавка к пище "селен-йод-эластин" | |
Xue et al. | Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour | |
ES2954594T3 (es) | Composiciones que comprenden aminoácidos para su uso en la prevención y el tratamiento de los efectos secundarios de la quimioterapia | |
San‐in Group of Liver Surgery | Long‐term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial | |
WO2022064079A1 (es) | Terapia metabólica del cáncer | |
US20120101057A1 (en) | Combined therapy of colorectal carcinoma | |
ES2342461T3 (es) | Agente de estroncio no radiactivo para tratar el cancer. | |
WO2019106626A1 (en) | Composition for oral administration, the use of the composition in prevention and treatment of mucositis, and a method of treatment of mucositis | |
JP2014529620A (ja) | 抗癌治療にリンクする副作用の予防または治療において低ポリアミン含有量を用いる組成物の使用 | |
Saltz | Drug treatment of colorectal cancer: current status | |
Correale et al. | Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer | |
Chung et al. | RX3117: activity of an oral antimetabolite nucleoside in subjects with pancreatic cancer–preliminary results of stage II of the phase Ia/IIb study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20800703 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3192176 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020800703 Country of ref document: EP Effective date: 20230303 |
|
ENP | Entry into the national phase |
Ref document number: 2023517757 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020468941 Country of ref document: AU Date of ref document: 20200923 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |